Results 11 to 20 of about 28,983 (181)

Oxygen reduction reaction on platinum single-crystal electrodes modified with protonic ionic liquid

Electrochemistry Communications, 2022
The oxygen reduction reaction (ORR) on the low- and high-index planes of Pt modified with a protonic ionic liquid ([7-methyl-1,5,7-triazabicyclo(4.4.0)dec-5-ene][bis(pentafluoroethylsulfonyl)imide], referred to here as [MTBD][beti]) was studied in 0.1 M ...
Rui Suzuki, Masashi Nakamura, Nagahiro Hoshi   +2 more
doaj   +1 more source

A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma

Pharmaceuticals, 2023
Background: There have been significant advancements in melanoma therapies. BET inhibitors (BETis) show promise in impairing melanoma growth. However, identifying BETi-sensitive melanoma subtypes is challenging.
Liuying Wang, Liuchao Zhang, Shuang Li, Lei Cao, Kang Li, Weiwei Zhao   +5 more
doaj   +1 more source

Targeting radioresistance and replication fork stability in prostate cancer

JCI Insight, 2022
The bromodomain and extraterminal (BET) family of chromatin reader proteins bind to acetylated histones and regulate gene expression. The development of BET inhibitors (BETi) has expanded our knowledge of BET protein function beyond transcriptional ...
Xiangyi Li, GuemHee Baek, Suzanne Carreira, Wei Yuan, Shihong Ma, Mia Hofstad, Sora Lee, Yunpeng Gao, Claudia Bertan, Maria de los Dolores Fenor de la Maza, Prasanna G. Alluri, Sandeep Burma, Benjamin P.C. Chen, Ganesh V. Raj, Johann de Bono, Yves Pommier, Ram S. Mani   +16 more
doaj   +1 more source

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

Journal of Market Access & Health Policy, 2021
Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation.
Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro   +9 more
doaj   +1 more source

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53

Neoplasia: An International Journal for Oncology Research, 2021
Amplification of MYCN is a poor prognostic feature in neuroblastoma (NBL) indicating aggressive disease. We and others have shown BET bromodomain inhibitors (BETi) target MYCN indirectly by downregulating its transcription.
Joanna S. Yi, Oscar Sias-Garcia, Nicole Nasholm, Xiaoyu Hu, Amanda Balboni Iniguez, Matthew D. Hall, Mindy Davis, Rajarshi Guha, Myrthala Moreno-Smith, Eveline Barbieri, Kevin Duong, Jessica Koach, Jun Qi, James E. Bradner, Kimberly Stegmaier, William A. Weiss, W. Clay Gustafson   +16 more
doaj   +1 more source

Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells

Molecular Therapy: Nucleic Acids, 2021
Neuroblastoma (NB) harboring MYCN amplification is a refractory disease with a poor prognosis. As BRD4, an epigenetic reader belonging to the bromodomain and extra terminal domain (BET) family, drives transcription of MYCN in NB cells, BET inhibitors ...
Chang Liu, Yasuyuki Gen, Kousuke Tanimoto, Tomoki Muramatsu, Jun Inoue, Johji Inazawa   +5 more
doaj   +1 more source

BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells

Journal of Experimental & Clinical Cancer Research, 2023
Background Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that differs from other types of breast cancers in the faster spread and worse outcome. TNBC presented limited treatment options.
Teresa Rossi, Raffaella Zamponi, Mattea Chirico, Maria Elena Pisanu, Egidio Iorio, Federica Torricelli, Mila Gugnoni, Alessia Ciarrocchi, Mariaelena Pistoni   +8 more
doaj   +1 more source

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Genes and Diseases, 2023
The bromodomain and extra-terminal (BET) proteins act as “readers” for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes.
Tao Ma, Yan Chen, Zhi-Gang Yi, Yan-Hong Li, Jun Bai, Li-Juan Li, Lian-Sheng Zhang   +6 more
doaj   +1 more source

The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells

Frontiers in Oncology, 2022
We reported previously that the BET inhibitor (BETi) JQ1 decreases levels of the DNA repair protein RAD51 and that this decrease is concomitant with increased levels of DNA damage.
Patrick L. Garcia, Aubrey L. Miller, Ling Zeng, Ling Zeng, Robert C. A. M. van Waardenburg, Eddy S. Yang, Eddy S. Yang, Eddy S. Yang, Karina J. Yoon   +8 more
doaj   +1 more source

Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancerResearch in context

EBioMedicine, 2019
Background: Bromodomain and extra-terminal inhibitors (BETi) have shown efficacy for the treatment of aggressive triple negative breast cancer (TNBC).
Sushmita Mustafi, Vladimir Camarena, Rehana Qureshi, Hyunho Yoon, Claude-Henry Volmar, Tyler C. Huff, David W. Sant, Lihong Zheng, Shaun P. Brothers, Claes Wahlestedt, Joyce Slingerland, Gaofeng Wang   +11 more
doaj   +1 more source